Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma

BACKGROUND: This phase I/II study aimed to determine the maximum tolerated dose (MTD) of nanoparticle albumin-bound paclitaxel (nab(®)-paclitaxel) plus cisplatin as treatment for metastatic nasopharyngeal carcinoma (NPC). METHODS: Patients were enrolled into 1 of 3 dose cohorts, each with 21-day tre...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Huang, Yan, Liang, Wenhua, Yang, Yunpeng, Zhao, Liping, Zhao, Hongyun, Wu, Xuan, Zhao, Yuanyuan, Zhang, Yang, Zhang, Li
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4944269/
https://ncbi.nlm.nih.gov/pubmed/27411683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2517-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares